Jacek Kubica

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/1557306/jacek-kubica-publications-by-year.pdf

Version: 2024-04-19

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

8,782 205 91 32 h-index g-index citations papers 280 11,026 5.81 3.7 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
205	Diurnal Variability of Platelet Aggregation in Patients with Myocardial Infarction Treated with Prasugrel and Ticagrelor <i>Journal of Clinical Medicine</i> , 2022 , 11,	5.1	1
204	Management and predictors of clinical events in 75 686 patients with acute myocardial infarction <i>Kardiologia Polska</i> , 2022 ,	0.9	4
203	Assessment of Selected Baseline and Post-PCI Electrocardiographic Parameters as Predictors of Left Ventricular Systolic Dysfunction after a First ST-Segment Elevation Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
202	Impact of COVID-19 pandemic on acute heart failure admissions and mortality: a multicentre study (COV-HF-SIRIO 6 study). <i>ESC Heart Failure</i> , 2021 , 9, 721	3.7	3
201	Low-dose ticagrelor with or without acetylsalicylic acid in patients with acute coronary syndrome: Rationale and design of the ELECTRA-SIRIO 2 trial. <i>Cardiology Journal</i> , 2021 ,	1.4	1
200	Repetitive use of LEvosimendan in Ambulatory Heart Failure patients (LEIA-HF) - The rationale and study design. <i>Advances in Medical Sciences</i> , 2021 , 67, 18-22	2.8	1
199	Ticagrelor vs Clopidogrel for Patients With Acute Coronary Syndrome Undergoing Percutaneous Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2021 , 325, 890	27.4	
198	Mild therapeutic hypothermia after out-of-hospital cardiac arrest: What does really matter?. <i>Cardiology Journal</i> , 2021 , 28, 293-301	1.4	
197	Evidence-Based Aerobic Exercise Training in Metabolic-Associated Fatty Liver Disease: Systematic Review with Meta-Analysis. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	6
196	Glasgow Coma Scale score of more than four on admission predicts in-hospital survival in patients after out-of-hospital cardiac arrest. <i>American Journal of Emergency Medicine</i> , 2021 , 42, 90-94	2.9	1
195	Cardiac mortality in patients randomised to elective coronary revascularisation plus medical therapy or medical therapy alone: a systematic review and meta-analysis. <i>European Heart Journal</i> , 2021 , 42, 4638-4651	9.5	21
194	Diagnostic Performance of Selected Baseline Electrocardiographic Parameters for Prediction of Left Ventricular Remodeling in Patients with ST-Segment Elevation Myocardial Infarction. <i>Journal of Clinical Medicine</i> , 2021 , 10,	5.1	1
193	Pharmacokinetic Modeling of Morphine@Effect on Plasma Concentrations of Ticagrelor and Its Metabolite in Healthy Volunteers. <i>Frontiers in Physiology</i> , 2021 , 12, 663170	4.6	O
192	Debate: Prasugrel rather than ticagrelor is the preferred treatment for NSTE-ACS patients who proceed to PCI and pretreatment should not be performed in patients planned for an early invasive strategy. <i>European Heart Journal</i> , 2021 , 42, 2973-2985	9.5	10
191	Development and Validation of a Practical Model to Identify Patients at Risk of Bleeding After TAVR. <i>JACC: Cardiovascular Interventions</i> , 2021 , 14, 1196-1206	5	6
190	Efficacy and safety of intracoronary epinephrine versus conventional treatments alone in STEMI patients with refractory coronary no-reflow during primary PCI: The RESTORE observational study. <i>Catheterization and Cardiovascular Interventions</i> , 2021 , 97, 602-611	2.7	7
189	Endogenous fibrinolysis-Relevance to clinical thrombosis risk assessment. <i>European Journal of Clinical Investigation</i> , 2021 , 51, e13471	4.6	2

188	Pharmacodynamic and clinical efficacy of reduced ticagrelor maintenance doses in patients with coronary artery disease. <i>Current Medical Research and Opinion</i> , 2021 , 37, 195-206	2.5	2
187	Antiplatelets in acute coronary syndrome in Poland - from guidelines to clinical practice. <i>Postepy W Kardiologii Interwencyjnej</i> , 2021 , 17, 141-154	0.4	0
186	Characteristics of patients from the Polish Registry of Acute Coronary Syndromes during the COVID-19 pandemic: the first report. <i>Kardiologia Polska</i> , 2021 , 79, 192-195	0.9	1
185	Low dose of ROSuvastatin in combination with EZEtimibe effectively and permanently reduce low density lipoprotein cholesterol concentration independently of timing of administration (ROSEZE): A randomized, crossover study - preliminary results. <i>Cardiology Journal</i> , 2021 , 28, 58-66	1.4	1
184	ANalgesic Efficacy and safety of MOrphiNe versus methoxyflurane in patients with acute myocardial infarction: the rationale and design of the ANEMON-SIRIO 3 study: a multicentre, open-label, phase II, randomised clinical trial. <i>BMJ Open</i> , 2021 , 11, e043330	3	1
183	C-Reactive Protein as a Risk Marker for Post-Infarct Heart Failure over a Multi-Year Period. <i>International Journal of Molecular Sciences</i> , 2021 , 22,	6.3	9
182	A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, placebo-controlled, investigator-initiated, multicenter clinical study. <i>Cardiology Journal</i> , 2021 , 28, 607-614	1.4	2
181	Lipoprotein(a) and Benefit of PCSK9 Inhibition in Patients With Nominally Controlled LDL Cholesterol. <i>Journal of the American College of Cardiology</i> , 2021 , 78, 421-433	15.1	13
180	Long-Term Outcomes Following Drug-Eluting Balloons Versus Thin-Strut Drug-Eluting Stents for Treatment of In-Stent Restenosis (DEB-Dragon-Registry). <i>Circulation: Cardiovascular Interventions</i> , 2021 , 14, e010868	6	1
179	Effects of SGLT2 Inhibitors on Ion Homeostasis and Oxidative Stress associated Mechanisms in Heart Failure. <i>Biomedicine and Pharmacotherapy</i> , 2021 , 143, 112169	7.5	6
178	Aspirin as an Adjunctive Pharmacologic Therapy Option for COVID-19: Anti-Inflammatory, Antithrombotic, and Antiviral Effects All in One Agent <i>Journal of Experimental Pharmacology</i> , 2021 , 13, 957-970	3	0
177	Comparative Efficacy and Safety of Oral P2Y Inhibitors in Acute Coronary Syndrome: Network Meta-Analysis of 52 816 Patients From 12 Randomized Trials. <i>Circulation</i> , 2020 , 142, 150-160	16.7	44
176	Transcatheter Aortic Valve Replacement with Self-Expandable ACURATE neo as Compared to Balloon-Expandable SAPIEN 3 in Patients with Severe Aortic Stenosis: Meta-Analysis of Randomized and Propensity-Matched Studies. <i>Journal of Clinical Medicine</i> , 2020 , 9,	5.1	2
175	Impact of Preadmission Morphine on Reinfarction in Patients With ST-Elevation Myocardial Infarction Treated With Percutaneous Coronary Intervention: A Meta-Analysis. <i>Clinical Pharmacology and Therapeutics</i> , 2020 , 108, 54-62	6.1	7
174	Enhanced Inflammation is a Marker for Risk of Post-Infarct Ventricular Dysfunction and Heart Failure. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	20
173	Transcatheter aortic valve replacement with Lotus and Sapien 3 prosthetic valves: a systematic review and meta-analysis. <i>Journal of Thoracic Disease</i> , 2020 , 12, 893-906	2.6	4
172	Medical emergency team interventions in patients with ST-segment elevation myocardial infarction in Poland in 2018. <i>Kardiologia Polska</i> , 2020 , 78, 292-299	0.9	1
171	Levosimendan in the treatment of patients with acute cardiac conditions: an expert opinion of the Association of Intensive Cardiac Care of the Polish Cardiac Society. <i>Kardiologia Polska</i> , 2020 , 78, 825-83-	4 ^{0.9}	4

170	Influence of QRS duration and axis on response to cardiac resynchronization therapy in chronic heart failure with reduced left ventricular ejection fraction: A single center study including patients with left bundle branch block. <i>Cardiology Journal</i> , 2020 , 27, 575-582	1.4	2
169	Impact of mild therapeutic hypothermia on bioavailability of ticagrelor in patients with acute myocardial infarction after out-of-hospital cardiac arrest. <i>Cardiology Journal</i> , 2020 , 27, 780-788	1.4	2
168	Ion channel inhibition against COVID-19: A novel target for clinical investigation. <i>Cardiology Journal</i> , 2020 , 27, 421-424	1.4	7
167	Prolonged antithrombotic therapy in patients after acute coronary syndrome: A critical appraisal of current European Society of Cardiology guidelines. <i>Cardiology Journal</i> , 2020 , 27, 661-676	1.4	4
166	Comparison of temperature measurements in esophagus and urinary bladder in comatose patients after cardiac arrest undergoing mild therapeutic hypothermia. <i>Cardiology Journal</i> , 2020 , 27, 735-741	1.4	2
165	Diurnal variations in tissue factor and tissue factor pathway inhibitor concentrations in relation to on-treatment platelet reactivity: an analysis of patients with acute myocardial infarction. <i>Platelets</i> , 2020 , 31, 877-883	3.6	1
164	State of the Art: No-Reflow Phenomenon. Cardiology Clinics, 2020, 38, 563-573	2.5	9
163	von Willebrand Factor Predicts Mortality in ACS Patients Treated with Potent P2Y12 Antagonists and is Inhibited by Aptamer BT200 Ex Vivo. <i>Thrombosis and Haemostasis</i> , 2020 , 120, 1282-1290	7	3
162	"Protocol for a phase 2, randomized, double-blind, placebo-controlled, safety and efficacy study of dutogliptin in combination with filgrastim in early recovery post-myocardial infarction": study protocol for a randomized controlled trial. <i>Trials</i> , 2020 , 21, 744	2.8	O
161	Platelet inhibition with standard vs. lower maintenance dose of ticagrelor early after myocardial infarction (ELECTRA): a randomized, open-label, active-controlled pharmacodynamic and pharmacokinetic study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 139-148	6.4	14
160	Risk of Statin-Induced Hypertransaminasemia: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Mayo Clinic Proceedings Innovations, Quality & Outcomes</i> , 2019 , 3, 131-14	03.1	4
159	Age-Related 2-Year Mortality After Transcatheter Aortic Valve Replacement: the YOUNG TAVR Registry. <i>Mayo Clinic Proceedings</i> , 2019 , 94, 1457-1466	6.4	12
158	Determinants of high platelet reactivity in patients with acute coronary syndromes treated with ticagrelor. <i>Scientific Reports</i> , 2019 , 9, 3924	4.9	6
157	Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial. <i>Lancet Diabetes and Endocrinology,the</i> , 2019 , 7, 618-628	18.1	120
156	Short-Term Therapies for Treatment of Acute and Advanced Heart Failure-Why so Few Drugs Available in Clinical Use, Why Even Fewer in the Pipeline?. <i>Journal of Clinical Medicine</i> , 2019 , 8,	5.1	9
155	Bivalirudin use in acute coronary syndrome patients undergoing percutaneous coronary interventions in Poland: Clinical update from expert group of the Association on Cardiovascular Interventions of the Polish Cardiac Society. <i>Cardiology Journal</i> , 2019 , 26, 1-7	1.4	4
154	Stratified Approaches to Antiplatelet Therapies Based on Platelet Reactivity Testing. <i>Frontiers in Cardiovascular Medicine</i> , 2019 , 6, 176	5.4	12
153	Transcathether aortic valve implantation with the new repositionable self-expandable Medtronic Evolut R vs. CoreValve system: evidence on the benefit of a meta-analytical approach. <i>Journal of Cardiovascular Medicine</i> , 2019 , 20, 226-236	1.9	6

152	A study of biological and lifestyle factors, including within-subject variation, affecting concentrations of growth differentiation factor 15 in serum. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019 , 57, 1035-1043	5.9	8
151	Safety and efficacy of self-apposing Stentys drug-eluting stent in left main coronary artery PCI: Multicentre LM-STENTYS registry. <i>Catheterization and Cardiovascular Interventions</i> , 2019 , 93, 574-582	2.7	1
150	Baseline low-density lipoprotein cholesterol to predict the extent of cardiovascular benefit from lipid-lowering therapies: a review. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2019 , 5, 47-54	6.4	9
149	Plasma midregional proadrenomedullin (MR-proADM) concentrations and their biological determinants in a reference population. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018 , 56, 1161-1168	8 ^{5.9}	11
148	Association Between Baseline LDL-C Level and Total and Cardiovascular Mortality After LDL-C Lowering: A Systematic Review and Meta-analysis. <i>JAMA - Journal of the American Medical Association</i> , 2018 , 319, 1566-1579	27.4	205
147	Comparative performance of transcatheter aortic valve-in-valve implantation versus conventional surgical redo aortic valve replacement in patients with degenerated aortic valve bioprostheses: systematic review and meta-analysis. <i>European Journal of Cardio-thoracic Surgery</i> , 2018 , 53, 495-504	3	40
146	Perioperative aspirin therapy in non-cardiac surgery: A systematic review and meta-analysis of randomized controlled trials. <i>International Journal of Cardiology</i> , 2018 , 258, 59-67	3.2	8
145	Morphine Interaction with Aspirin: a Double-Blind, Crossover Trial in Healthy Volunteers. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2018 , 365, 430-436	4.7	4
144	Rationale and Design of the Effectiveness of LowEr maintenanCe dose of TicagRelor early After myocardial infarction (ELECTRA) pilot study. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2018 , 4, 152-157	6.4	15
143	Dual vs single antiplatelet therapy in patients with lower extremity peripheral artery disease - A meta-analysis. <i>International Journal of Cardiology</i> , 2018 , 269, 292-297	3.2	10
142	Role of proprotein convertase subtilisin/kexin type 9 inhibitors in patients with coronary artery disease undergoing percutaneous coronary intervention. <i>Expert Review of Cardiovascular Therapy</i> , 2018 , 16, 419-429	2.5	4
141	Evaluating current and emerging antithrombotic therapy currently available for the treatment of acute coronary syndrome in geriatric populations. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1415-1	425	6
140	Cangrelor for the treatment of patients with Arterial Thrombosis. <i>Expert Opinion on Pharmacotherapy</i> , 2018 , 19, 1389-1398	4	3
139	Metabolism of ticagrelor in patients with acute coronary syndromes. <i>Scientific Reports</i> , 2018 , 8, 11746	4.9	11
138	Treatment of patients with acute coronary syndrome: Recommendations for medical emergency teams: Focus on antiplatelet therapies. Updated experts@tandpoint. <i>Cardiology Journal</i> , 2018 , 25, 291-	3 00	12
137	METoclopramide Administration as a Strategy to Overcome MORPHine-ticagrelOr Interaction in PatientS with Unstable Angina PectorIS-The METAMORPHOSIS Trial. <i>Thrombosis and Haemostasis</i> , 2018 , 118, 2126-2133	7	28
136	Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome. <i>New England Journal of Medicine</i> , 2018 , 379, 2097-2107	59.2	1277
135	High-sensitivity cardiac troponin assays: From improved analytical performance to enhanced risk stratification. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017 , 54, 143-172	9.4	31

134	Comparison of Ticagrelor Pharmacokinetics and Pharmacodynamics in STEMI and NSTEMI Patients (PINPOINT): protocol for a prospective, observational, single-centre study. <i>BMJ Open</i> , 2017 , 7, e013218	3 3	8
133	Repetitive use of levosimendan in advanced heart failure: need for stronger evidence in a field in dire need of a useful therapy. <i>International Journal of Cardiology</i> , 2017 , 243, 389-395	3.2	21
132	Establishing reference intervals for galectin-3 concentrations in serum requires careful consideration of its biological determinants. <i>Clinical Biochemistry</i> , 2017 , 50, 599-604	3.5	9
131	Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease. <i>New England Journal of Medicine</i> , 2017 , 376, 1713-1722	59.2	2700
130	Impact of levosimendan on platelet function. <i>Thrombosis Research</i> , 2017 , 159, 76-81	8.2	5
129	Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. <i>PLoS ONE</i> , 2017 , 12, e0168726	3.7	19
128	The impact of the time of drug administration on the effectiveness of combined treatment of hypercholesterolemia with Rosuvastatin and Ezetimibe (RosEze): study protocol for a randomized controlled trial. <i>Trials</i> , 2017 , 18, 316	2.8	4
127	Crushed sublingual versus oral ticagrelor administration strategies in patients with unstable angina. A pharmacokinetic/pharmacodynamic study. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 718-726	7	22
126	High-risk percutaneous coronary intervention with Impella CP hemodynamic support. A case series and method presentation. <i>Postepy W Kardiologii Interwencyjnej</i> , 2017 , 13, 67-71	0.4	1
125	Implantable Cardioverter-Defibrillators for Primary Prevention in Patients With Ischemic or Nonischemic Cardiomyopathy: A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2017 , 167, 103-111	8	30
124	Prasugrel in critically ill patients. <i>Thrombosis and Haemostasis</i> , 2017 , 117, 1582-1587	7	8
123	Comparison of bioavailability and antiplatelet action of ticagrelor in patients with ST-elevation myocardial infarction and non-ST-elevation myocardial infarction: A prospective, observational, single-centre study. <i>PLoS ONE</i> , 2017 , 12, e0186013	3.7	14
122	Anti-aggregation therapy in patients with acute coronary syndrome - recommendations for medical emergency teams. Experts&tandpoint. <i>Kardiologia Polska</i> , 2017 , 75, 399-408	0.9	4
121	Admission glucose and left ventricular systolic function in non-diabetic patients with acute myocardial infarction. <i>Heart and Vessels</i> , 2016 , 31, 298-307	2.1	4
120	Current controversies in the use of aspirin and ticagrelor for the treatment of thrombotic events. <i>Expert Review of Cardiovascular Therapy</i> , 2016 , 14, 1361-1370	2.5	3
119	Morphine delays and attenuates ticagrelor exposure and action in patients with myocardial infarction: the randomized, double-blind, placebo-controlled IMPRESSION trial. <i>European Heart Journal</i> , 2016 , 37, 245-52	9.5	172
118	Morphine decreases ticagrelor concentrations but not its antiplatelet effects: a randomized trial in healthy volunteers. <i>European Journal of Clinical Investigation</i> , 2016 , 46, 7-14	4.6	42
117	Cause of Death and Predictors of All-Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF. <i>Journal of the American Heart Association</i> , 2016 , 5, e002197	6	94

116	Prediction of high risk of non-adherence to antiplatelet treatment. Kardiologia Polska, 2016, 74, 61-7	0.9	12
115	Impact of ticagrelor administration strategy on its pharmacokinetics and pharmacodynamics in patients with unstable angina pectoris: a protocol of a randomized study. <i>Medical Research Journal</i> , 2016 , 1, 10-14	2.3	3
114	Circulatory support with Impella CP device during high-risk percutaneous coronary interventions: initial experience in Poland. <i>Postepy W Kardiologii Interwencyjnej</i> , 2016 , 12, 254-7	0.4	4
113	Effect of chokeberry juice consumption on antioxidant capacity, lipids profile and endothelial function in healthy people: a pilot study. <i>Czech Journal of Food Sciences</i> , 2016 , 34, 39-46	1.3	11
112	Which platelet function test best reflects the in vivo plasma concentrations of ticagrelor and its active metabolite? The HARMONIC study. <i>Thrombosis and Haemostasis</i> , 2016 , 116, 1140-1149	7	9
111	State of the art: Oral antiplatelet therapy. JRSM Cardiovascular Disease, 2016, 5, 2048004016652514	1.1	5
110	Impact of morphine on antiplatelet effects of oral P2Y12 receptor inhibitors. <i>International Journal of Cardiology</i> , 2016 , 215, 201-8	3.2	48
109	Adherence to antiplatelet treatment with P2Y12 receptor inhibitors. Is there anything we can do to improve it? A systematic review of randomized trials. <i>Current Medical Research and Opinion</i> , 2016 , 32, 1441-51	2.5	14
108	Abciximab as a bridging strategy to overcome morphine-prasugrel interaction in STEMI patients. <i>British Journal of Clinical Pharmacology</i> , 2016 , 82, 1343-1350	3.8	27
107	New directions for pharmacotherapy in the treatment of acute coronary syndrome. <i>Expert Opinion on Pharmacotherapy</i> , 2016 , 17, 2291-2306	4	9
106	Impact of lipid markers and high-sensitivity C-reactive protein on the value of the 99th percentile upper reference limit for high-sensitivity cardiac troponin I. <i>Clinica Chimica Acta</i> , 2016 , 462, 193-200	6.2	4
106		6.2 3.9	4
	upper reference limit for high-sensitivity cardiac troponin I. <i>Clinica Chimica Acta</i> , 2016 , 462, 193-200 Acetylsalicylic acid resistance risk factors in patients with myocardial infarction. <i>Pharmacological Reports</i> , 2015 , 67, 952-8 Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and		
105	upper reference limit for high-sensitivity cardiac troponin I. <i>Clinica Chimica Acta</i> , 2016 , 462, 193-200 Acetylsalicylic acid resistance risk factors in patients with myocardial infarction. <i>Pharmacological Reports</i> , 2015 , 67, 952-8 Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The	3.9	4
105	upper reference limit for high-sensitivity cardiac troponin I. <i>Clinica Chimica Acta</i> , 2016 , 462, 193-200 Acetylsalicylic acid resistance risk factors in patients with myocardial infarction. <i>Pharmacological Reports</i> , 2015 , 67, 952-8 Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study. Complete revascularisation in ST-elevation myocardial infarction and multivessel disease:	3.9	11
105	Acetylsalicylic acid resistance risk factors in patients with myocardial infarction. <i>Pharmacological Reports</i> , 2015 , 67, 952-8 Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study. Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. <i>Heart</i> , 2015 , 101, 1309-17 Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2015 ,	3.9 3.2 5.1	11 35
105 104 103	upper reference limit for high-sensitivity cardiac troponin I. <i>Clinica Chimica Acta</i> , 2016 , 462, 193-200 Acetylsalicylic acid resistance risk factors in patients with myocardial infarction. <i>Pharmacological Reports</i> , 2015 , 67, 952-8 Efficacy of cilostazol on inhibition of platelet aggregation, inflammation and myonecrosis in acute coronary syndrome patients undergoing percutaneous coronary intervention: The ACCEL-LOADING-ACS (ACCELerated Inhibition of Platelet Aggregation, Inflammation and Myonecrosis by Adjunctive Cilostazol Loading in Patients With Acute Coronary Syndrome) study. Complete revascularisation in ST-elevation myocardial infarction and multivessel disease: meta-analysis of randomised controlled trials. <i>Heart</i> , 2015 , 101, 1309-17 Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. <i>Annals of Internal Medicine</i> , 2015 , 163, 40-51 Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction (IMPRESSION): study protocol for a randomized controlled trial. <i>Trials</i> ,	3.9 3.2 5.1 8	4 11 35 281

98	The number of circulating endothelial progenitor cells in healthy individualseffect of some anthropometric and environmental factors (a pilot study). <i>Advances in Medical Sciences</i> , 2015 , 60, 58-63	2.8	7
97	A novel multiplex assay amplifying 13 Y-STRs characterized by rapid and moderate mutation rate. <i>Forensic Science International: Genetics</i> , 2015 , 15, 49-55	4.3	17
96	Personalized antiplatelet therapy with P2Y12 receptor inhibitors: benefits and pitfalls. <i>Postepy W Kardiologii Interwencyjnej</i> , 2015 , 11, 259-80	0.4	21
95	Use of time-resolved fluorescence spectroscopy to evaluate diagnostic value of collagen degradation products. <i>Journal of Biomedical Optics</i> , 2015 , 20, 051039	3.5	2
94	Associations between selected angiographic parameters and the number of CD34+ cells and plasma levels of vascular endothelial growth factor and angiogenin in patients with ST-segment elevation myocardial infarction. <i>Polish Archives of Internal Medicine</i> , 2015 , 125, 132-40	1.9	2
93	Statins and risk of new-onset diabetes mellitus: is there a rationale for individualized statin therapy?. <i>American Journal of Cardiovascular Drugs</i> , 2014 , 14, 79-87	4	22
92	Meta-analysis of time-related benefits of statin therapy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. <i>American Journal of Cardiology</i> , 2014 , 113, 1753-64	3	51
91	First-generation versus second-generation drug-eluting stents in current clinical practice: updated evidence from a comprehensive meta-analysis of randomised clinical trials comprising 31 379 patients. <i>Open Heart</i> , 2014 , 1, e000064	3	70
90	Time-related changes in determinants of antiplatelet effect of clopidogrel in patients after myocardial infarction. <i>European Journal of Pharmacology</i> , 2014 , 742, 47-54	5.3	26
89	Platelet Receptors and Drug Targets 2014 , 21-28		
89 88	Platelet Receptors and Drug Targets 2014 , 21-28 Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. <i>Clinical Research in Cardiology</i> , 2014 , 103, 855-86	6.1	14
	Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an	6.1 9·5	14
88	Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. <i>Clinical Research in Cardiology</i> , 2014 , 103, 855-86 Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart		·
88 8 ₇	Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. <i>Clinical Research in Cardiology</i> , 2014 , 103, 855-86 Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. <i>European Heart Journal</i> , 2014 , 35, 2295-302 Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. <i>Atherosclerosis</i> , 2014 ,	9.5	100
88 87 86	Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. <i>Clinical Research in Cardiology</i> , 2014 , 103, 855-86 Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. <i>European Heart Journal</i> , 2014 , 35, 2295-302 Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. <i>Atherosclerosis</i> , 2014 , 233, 224-31 Critical appraisal of inflammatory markers in cardiovascular risk stratification. <i>Critical Reviews in</i>	9.5	100
88 87 86 85	Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. <i>Clinical Research in Cardiology</i> , 2014 , 103, 855-86 Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. <i>European Heart Journal</i> , 2014 , 35, 2295-302 Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. <i>Atherosclerosis</i> , 2014 , 233, 224-31 Critical appraisal of inflammatory markers in cardiovascular risk stratification. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014 , 51, 263-79 Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse	9·5 3·1 9·4	100 24 54
88 87 86 85 84	Clinical significance of Helicobacter pylori infection in patients with acute coronary syndromes: an overview of current evidence. <i>Clinical Research in Cardiology</i> , 2014 , 103, 855-86 Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: the Randomized Double-Blind Reminder Study. <i>European Heart Journal</i> , 2014 , 35, 2295-302 Short and long-term safety and efficacy of polymer-free vs. durable polymer drug-eluting stents. A comprehensive meta-analysis of randomized trials including 6178 patients. <i>Atherosclerosis</i> , 2014 , 233, 224-31 Critical appraisal of inflammatory markers in cardiovascular risk stratification. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2014 , 51, 263-79 Interplay between genetic and clinical variables affecting platelet reactivity and cardiac adverse events in patients undergoing percutaneous coronary intervention. <i>PLoS ONE</i> , 2014 , 9, e102701 Overview of pleiotropic effects of platelet P2Y12 receptor inhibitors. <i>Thrombosis and Haemostasis</i> ,	9.5 3.1 9.4 3.7	100245421

80	Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up. <i>Cardiology Journal</i> , 2014 , 21, 547-	5 1 64	16
79	Influence of cardiac resynchronization therapy on oxidative stress markers in patients with chronic heart failure. <i>Cardiology Journal</i> , 2014 , 21, 576-82	1.4	4
78	Optimal timing of coronary invasive strategy in non-ST-segment elevation acute coronary syndromes: a systematic review and meta-analysis. <i>Annals of Internal Medicine</i> , 2013 , 158, 261-70	8	115
77	Drug-coated balloons in treatment of in-stent restenosis: a meta-analysis of randomised controlled trials. <i>Clinical Research in Cardiology</i> , 2013 , 102, 279-87	6.1	21
76	Low-dose of oral factor Xa inhibitors in patients with a recent acute coronary syndrome: a systematic review and meta-analysis of randomized trials. <i>Atherosclerosis</i> , 2013 , 229, 482-8	3.1	6
75	A critical overview on ticagrelor in acute coronary syndromes. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2013 , 106, 105-15	2.7	15
74	Neither cyclosporine nor tacrolimus deteriorate endothelial function in renal transplant recipients assessed with reactive hyperernia index. <i>Transplantation Proceedings</i> , 2013 , 45, 1567-70	1.1	2
73	Meta-analysis of impact of different types and doses of statins on new-onset diabetes mellitus. American Journal of Cardiology, 2013 , 111, 1123-30	3	190
72	Influence of genetic polymorphisms on platelet function, response to antiplatelet drugs and clinical outcomes in patients with coronary artery disease. <i>Expert Review of Cardiovascular Therapy</i> , 2013 , 11, 447-62	2.5	16
71	ACS network-based implementation of therapeutic hypothermia for the treatment of comatose out-of-hospital cardiac arrest survivors improves clinical outcomes: the first European experience. <i>Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine</i> , 2013 , 21, 22	3.6	15
70	High-dose, but not low-dose, aspirin impairs anticontractile effect of ticagrelor following ADP stimulation in rat tail artery smooth muscle cells. <i>BioMed Research International</i> , 2013 , 2013, 928271	3	9
69	Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. <i>BMJ</i> , <i>The</i> , 2013 , 347, f6530	5.9	166
68	Manual vs mechanical thrombectomy during PCI for STEMI: a comprehensive direct and adjusted indirect meta-analysis of randomized trials. <i>American Journal of Cardiovascular Disease</i> , 2013 , 3, 146-57	0.9	8
67	Six-month IVUS and two-year clinical outcomes in the EVOLVE FHU trial: a randomised evaluation of a novel bioabsorbable polymer-coated, everolimus-eluting stent. <i>EuroIntervention</i> , 2013 , 9, 308-15	3.1	34
66	Does mobilisation of CD34+ stem cells along with VEGF, angiogenin, IL-6, IL-8, and hsCRP levels allow predicting the direction of left ventricular ejection fraction and wall motion score index changes in patients with myocardial infarction?. <i>Kardiologia Polska</i> , 2013 , 71, 464-71	0.9	3
65	Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: the PEGASUS-PCI study. <i>Journal of Thrombosis and Haemostasis</i> , 2012 , 10, 529-42	15.4	73
64	Stress hyperglycaemia in patients with first myocardial infarction. <i>International Journal of Clinical Practice</i> , 2012 , 66, 592-601	2.9	13
63	Adenosine improves post-procedural coronary flow but not clinical outcomes in patients with acute coronary syndrome: a meta-analysis of randomized trials. <i>Atherosclerosis</i> , 2012 , 222, 1-7	3.1	32

62	Clinical efficacy and safety of intracoronary vs. intravenous abciximab administration in STEMI patients undergoing primary percutaneous coronary intervention: a meta-analysis of randomized trials. <i>Platelets</i> , 2012 , 23, 274-81	3.6	23
61	Ticagrelor, but not clopidogrel and prasugrel, prevents ADP-induced vascular smooth muscle cell contraction: a placebo-controlled study in rats. <i>Thrombosis Research</i> , 2012 , 130, 65-9	8.2	37
60	Ticagrelor in the treatment of coronary artery disease patients. <i>Clinical Practice (London, England)</i> , 2012 , 9, 373-390	3	
59	Caution in interpreting the findings from small observational studies. <i>International Journal of Cardiology</i> , 2012 , 160, 71	3.2	
58	Twelve-month results of a paclitaxel releasing balloon in patients presenting with in-stent restenosis First-in-Man (PEPPER) trial. <i>Cardiovascular Revascularization Medicine</i> , 2012 , 13, 260-4	1.6	29
57	Endothelial cell markers in coronary artery disease. <i>Postepy W Kardiologii Interwencyjnej</i> , 2012 , 4, 275-	2 79 .4	
56	Usefulness of C-reactive protein as a marker of early post-infarct left ventricular systolic dysfunction. <i>Inflammation Research</i> , 2012 , 61, 725-34	7.2	15
55	Value of C-reactive protein in predicting left ventricular remodelling in patients with a first ST-segment elevation myocardial infarction. <i>Mediators of Inflammation</i> , 2012 , 2012, 250867	4.3	25
54	Value of C-reactive protein as a risk factor for acute coronary syndrome: a comparison with apolipoprotein concentrations and lipid profile. <i>Mediators of Inflammation</i> , 2012 , 2012, 419804	4.3	14
53	Updated evidence on intracoronary abciximab in ST-elevation myocardial infarction: a systematic review and meta-analysis of randomized clinical trials. <i>Cardiology Journal</i> , 2012 , 19, 230-42	1.4	8
52	Occurrence and predictors of left ventricular systolic dysfunction at hospital discharge and in long-term follow-up after acute myocardial infarction treated with primary percutaneous coronary intervention. <i>Kardiologia Polska</i> , 2012 , 70, 329-40	0.9	6
51	Diurnal variation in platelet inhibition by clopidogrel. <i>Platelets</i> , 2011 , 22, 579-87	3.6	45
50	"Sirolimus or paclitaxel drug eluting stent in left main disease: the winner is". <i>International Journal of Cardiology</i> , 2011 , 152, 387	3.2	2
49	Diagnostic efficacy of myeloperoxidase for the detection of acute coronary syndromes. <i>European Journal of Clinical Investigation</i> , 2011 , 41, 667-71	4.6	20
48	Low-molecular-weight heparins vs. unfractionated heparin in the setting of percutaneous coronary intervention for ST-elevation myocardial infarction: a meta-analysis. <i>Journal of Thrombosis and Haemostasis</i> , 2011 , 9, 1902-15	15.4	61
47	Value of oral glucose tolerance test in the acute phase of myocardial infarction. <i>Cardiovascular Diabetology</i> , 2011 , 10, 21	8.7	8
46	Intracoronary versus intravenous abciximab administration in STEMI patients: overview of current status and open questions. <i>Current Medical Research and Opinion</i> , 2011 , 27, 2133-44	2.5	8
45	Efficacy and safety of celivarone, with amiodarone as calibrator, in patients with an implantable cardioverter-defibrillator for prevention of implantable cardioverter-defibrillator interventions or death: the ALPHEE study. <i>Circulation</i> , 2011 , 124, 2649-60	16.7	35

(2008-2011)

44	elevation: a meta-analysis of randomized studies. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011 , 104, 193-200	2.7	33
43	Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: a meta-analysis of randomized trials. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2011 , 104, 561-9	2.7	32
42	How Do Apolipoproteins ApoB and ApoA-I Perform in Patients with Acute Coronary Syndromes. <i>Journal of Medical Biochemistry</i> , 2011 , 30, 237-243	1.9	11
41	Impact of clopidogrel loading dose on clinical outcome in patients undergoing percutaneous coronary intervention: a systematic review and meta-analysis. <i>Heart</i> , 2011 , 97, 98-105	5.1	52
40	Safety and efficacy of biodegradable vs. durable polymer drug-eluting stents: evidence from a meta-analysis of randomised trials. <i>EuroIntervention</i> , 2011 , 7, 985-94	3.1	84
39	Impact of diabetes on survival in patients with ST-segment elevation myocardial infarction treated by primary angioplasty: insights from the POLISH STEMI registry. <i>Atherosclerosis</i> , 2010 , 210, 516-20	3.1	32
38	Influence of different antiplatelet treatment regimens for primary percutaneous coronary intervention on all-cause mortality. <i>European Heart Journal</i> , 2009 , 30, 1736-43	9.5	13
37	The Use of Biochip Cardiac Array Technology for Early Diagnosis of Acute Coronary Syndromes. Journal of Medical Biochemistry, 2009 , 28, 293-299	1.9	7
36	Reliability of heart rate variability measurements in patients with a history of myocardial infarction. <i>Clinical Science</i> , 2009 , 118, 195-201	6.5	26
35	Pantoprazole may enhance antiplatelet effect of enteric-coated aspirin in patients with acute coronary syndrome. <i>Cardiology Journal</i> , 2009 , 16, 535-44	1.4	21
34	Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2008 , 372, 807-16	40	775
33	The BEAUTIFUL study: randomized trial of ivabradine in patients with stable coronary artery disease and left ventricular systolic dysfunction - baseline characteristics of the study population. <i>Cardiology</i> , 2008 , 110, 271-82	1.6	33
32	Gender differences and in-hospital mortality in patients undergoing percutaneous coronary interventions. <i>Kardiologia Polska</i> , 2008 , 66, 632-9; discussion 640-1	0.9	4
31	No-reflow phenomenon: Achilles Queel of primary coronary angioplasty in acute myocardial infarction. <i>Cardiology Journal</i> , 2008 , 15, 1-3	1.4	5
30	The reliability of noninvasive cardiac output measurement using the inert gas rebreathing method in patients with advanced heart failure. <i>Cardiology Journal</i> , 2008 , 15, 63-70	1.4	15
29	Immunoglobulin E in patients with ischemic heart disease. Cardiology Journal, 2008, 15, 122-8	1.4	16
28	Predicted and observed in-hospital mortality after left main coronary artery stenting in 204 patients. <i>Cardiology Journal</i> , 2008 , 15, 268-76	1.4	4
27	The effect of trimetazidine added to maximal anti-ischemic therapy in patients with advanced coronary artery disease. <i>Cardiology Journal</i> , 2008 , 15, 344-50	1.4	11

26	Increased morning ADP-dependent platelet aggregation persists despite dual antiplatelet therapy in patients with first ST-segment elevation myocardial infarction: Preliminary report. <i>Cardiology Journal</i> , 2008 , 15, 530-6	1.4	7
25	Usefulness of optical coherence tomography in the assessment of atherosclerotic culprit lesions in acute coronary syndromes. Comparison with intravascular ultrasound and virtual histology. <i>Cardiology Journal</i> , 2008 , 15, 561-3	1.4	2
24	Periprocedural soluble P- and E-selectin levels fail as predictors of clinical restenosis in patients treated with elective coronary stenting. <i>International Journal of Molecular Medicine</i> , 2007 , 19, 187	4.4	
23	Comparison of angiographically guided direct stenting technique with direct stenting and optimal balloon angioplasty guided with intravascular ultrasound. The multicenter, randomized trial results. <i>American Heart Journal</i> , 2007 , 154, 669-75	4.9	31
22	One-year outcomes of left main coronary artery stenting in patients with cardiogenic shock. <i>Cardiology Journal</i> , 2007 , 14, 67-75	1.4	5
21	Percutaneous coronary angioplasty in elderly patients: Assessment of in-hospital outcomes. <i>Cardiology Journal</i> , 2007 , 14, 143-54	1.4	3
20	Immunoglobulin E as a marker of the atherothrombotic process in patients with acute myocardial infarction. <i>Cardiology Journal</i> , 2007 , 14, 266-73	1.4	5
19	Smokers versus non-smokers undergoing percutaneous transluminal coronary angioplasty: The impact of clinical and procedural characteristics on in-hospital mortality. <i>Cardiology Journal</i> , 2007 , 14, 482-92	1.4	7
18	Endothelial function parameters in patients with unstable angina and infection with Helicobacter pylori and Chlamydia pneumoniae. <i>European Journal of Internal Medicine</i> , 2006 , 17, 339-42	3.9	13
17	Percutaneous coronary intervention triggers a systemic inflammatory response in patients treated for in-stent restenosis comparison with stable and unstable angina. <i>Inflammation Research</i> , 2005 , 54, 187-93	7.2	25
16	Combined periprocedural evaluation of CRP and TNF-alpha enhances the prediction of clinical restenosis and major adverse cardiac events in patients undergoing percutaneous coronary interventions. <i>International Journal of Molecular Medicine</i> , 2005 , 16, 173-80	4.4	17
15	Threshold parameters of left main coronary artery stem stenosis based on intracoronary ultrasound examination. <i>Kardiologia Polska</i> , 2005 , 63, 223-31; discussion 232-3	0.9	9
14	Myocardial infarction with normal coronary arteriogram: the role of ephedrine-like alkaloids. <i>Medical Science Monitor</i> , 2004 , 10, CS15-21	3.2	9
13	Left ventricle systolic volume in vasovagal syncope patients. <i>Folia Morphologica</i> , 2003 , 62, 175-8	0.9	3
12	Analysis of the relationship between the inner structure and the magnitude of atherosclerotic plaques. <i>Folia Morphologica</i> , 2003 , 62, 369-75	0.9	
11	Antibodies to Chlamydia pneumoniae and haemostatic factors in acute coronary syndrome without ST segment elevation. <i>Kardiologia Polska</i> , 2002 , 57, 297-305	0.9	1
10	Endothelial dysfunction in acute coronary syndrome without ST segment elevation in the presence of Helicobacter pylori infection. <i>Kardiologia Polska</i> , 2002 , 57, 533-4; discussion 541	0.9	2
9	Correlation between clinical and morphologic findings in unstable angina. <i>American Journal of Cardiology</i> , 1996 , 77, 128-32	3	17

LIST OF PUBLICATIONS

8	Influence of plaque composition on luminal gain after balloon angioplasty, directional atherectomy, and coronary stenting. <i>American Heart Journal</i> , 1995 , 130, 971-5	4.9	10
7	Effects of coronary angioplasty on left ventricular function. <i>American Journal of Cardiology</i> , 1993 , 72, 119G-123G	3	4
6	Assessment of left ventricular function by isometric handgrip exercise after thrombolysis in patients with refractory unstable angina. <i>American Journal of Cardiology</i> , 1993 , 72, 140G-144G	3	
5	Influence of elastic recoil on restenosis after successful coronary angioplasty in unstable angina pectoris. <i>American Journal of Cardiology</i> , 1993 , 71, 659-63	3	18
4	Atrioventricular conduction disturbances in patients with sinoatrial node disease and atrial pacing. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1992 , 15, 2074-6	1.6	7
3	Left atrial size and wall motion in patients with permanent ventricular and atrial pacing. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990 , 13, 1737-41	1.6	13
2	Transesophageal atrial pacing complications in patients suspected of tachy-brady syndrome. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1990 , 13, 2048-53	1.6	3
1	Transesophageal programmed atrial pacing as a method of selecting patients with sick sinus syndrome for permanent atrial pacing. <i>PACE - Pacing and Clinical Electrophysiology</i> , 1988 , 11, 1655-61	1.6	3